Trial Profile
PARAGON: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Oct 2021
Price :
$35
*
At a glance
- Drugs Anastrozole (Primary)
- Indications Carcinoma; Endometrial cancer; Fallopian tube cancer; Leiomyosarcoma; Ovarian cancer; Peritoneal cancer; Sarcoma; Uterine cancer
- Focus Therapeutic Use
- Acronyms PARaGoN
- 27 Oct 2021 Status changed from active, no longer recruiting to completed.
- 05 Oct 2021 Results (N=39), of an analysis assessing the activity of anastrozole in two rare cohorts, with recurrent/metastatic uterine leiomyosarcomas and carcinosarcomas published in the Gynecologic Oncology
- 16 Aug 2021 Results (n=41) assessing efficacy and safety data from patients enrolled in recurrent/metastatic GCT and SCSTs arms published in the Gynecologic Oncology